For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Ranbaxy to Market Levofloxacin, Ofloxacin in Singapore: Daiichi Sankyo
March 14, 2011
- Takeda Licenses PDE1 Inhibitors from ITI
March 14, 2011
- Japan's Biosimilars Market Has Strong Growth Potential: Mr George of Sandoz
March 14, 2011
- Terumo Acquires CaridianBCT for US$2.6 Bil.
March 14, 2011
- Memantine, Galantamine Enter NHI Price List
March 14, 2011
- EC to Maintain Approval of Avastin + Paclitaxel for Metastatic Breast Cancer
March 14, 2011
- New Task Force to Be Created for Reform of Pharmaceutical Regulations
March 14, 2011
- Restriction on Use of Multiple Drugs in the Elderly Needs Careful Review: Dr Adachi
March 14, 2011
- JPMA Introduces GL for Disclosure of Funds Provided to Healthcare Professionals
March 14, 2011
- Terumo to Launch DuraHeart in April
March 14, 2011
- Zyprexa Applied for Depressive Symptoms Associated with Bipolar Disorders
March 14, 2011
- Terumo's Drug-eluting Stent Recommended for Approval
March 14, 2011
- Warfarin Approved for Pediatric Use: Eisai
March 7, 2011
- Korosho Calls on Generic Firms to Apply for New Indications Based on Data from Public Domain
March 7, 2011
- HbA1c to Be Reported in Int'l Units from April 2012 at the Earliest
March 7, 2011
- Higher Dose of Finibax Recommended for Approval
March 7, 2011
- 5 Brands of New Class 1 OTC Drugs Recommended for Approval
March 7, 2011
- Merck Serono Aims to Increase Market Share for Saizen
March 7, 2011
- Chuikyo to Weigh Premium-Derived Profits, Cost of Development of Unapproved Drugs
March 7, 2011
- Fuji Pharma to Join JGA
March 7, 2011
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…